Every pharma collateral is shaped by two forces that pull in opposite directions.
The marketing team wants the collateral to stand out. Bold visuals. A sharp headline. A story that holds the doctor’s attention in a room full of competing brands. They want something the MR is excited to present.
The medical team wants the collateral to be safe. Every claim backed by a valid reference. Every comparison supported by appropriate study design. Every visual compliant with applicable regulations. They want something that will not expose the company to risk.
Both are right. Both are doing exactly what they should be doing. And yet, in practice, these two objectives fight each other in almost every cycle.
How a strong collateral becomes a compromise document
Following is how it typically plays out.
The brand manager works with the creative agency. They build a collateral that tells a clear story. The visuals support the narrative. The headline is sharp. The flow makes sense. The brand manager is proud of it.
Then it goes for medical review.
Medical flags the headline because the claim it implies is not directly supported by the referenced study. The comparison chart needs a different framing because the evidence is from a post hoc analysis, not a pre-specified endpoint. The visual showing patient outcomes needs additional disclaimers. The safety section needs to be expanded.
Each flag is valid. Each one protects the company. But each one also requires a change that pulls the collateral further from what marketing intended.
The brand manager goes back to the agency. The headline gets softened. The comparison chart gets qualified with additional text. The visual gets replaced with something safer but less impactful. The reference section expands, pushing content to additional pages.
By the second or third round, the collateral looks different from what anyone originally envisioned. The sharp headline is now a careful statement. The clean visual flow is interrupted by qualifiers and footnotes. The story that was supposed to hold attention now reads like a compromise document. Which, in fact, it is.
Nobody planned this outcome. Marketing did not set out to create something weak. Medical did not set out to dilute the message. Both teams did their jobs well. The result is still a collateral that neither team is proud of.
The real issue is timing, not talent
The deeper issue is timing.
In most pharma companies, creative development and medical review happen sequentially. The brand team builds the collateral first, investing weeks of effort and often significant agency costs. Medical sees the output after creative work is substantially complete. By that point, every medical flag requires rework that is both expensive and emotionally difficult.
This sequential process turns two teams that should be collaborating into two teams that are negotiating. Medical is not the enemy of good creative work. But when medical sees the collateral for the first time as a near-finished product, their only available action is to flag issues. They cannot contribute to the creative direction because the creative direction was set without them.
What the best brand managers do differently
The brand managers who handle this best share one trait. They involve medical early. Not for formal review. For a conversation. Before the creative agency builds the first draft, the brand manager sits with the medical team and walks through the planned narrative. What claims are we leading with? What evidence supports them? What are the boundaries of what we can say?
When this conversation happens before creative work begins, the entire dynamic shifts. Medical is no longer the team that says no. They become the team that helped define what yes looks like. The creative brief reflects medical reality from the start. The agency builds within boundaries that have already been discussed. The first draft is closer to something that will survive review.
This sounds obvious. But it rarely happens. Because the typical brand cycle does not build time for this early conversation. The cycle meeting sets the deadline. The agency gets briefed. The clock starts. There is no structured moment in most companies’ processes for marketing and medical to align before creative development begins.
Process shapes output more than talent
The tension between creative ambition and medical rigour is not a problem to be solved. It is a tension to be managed. And the single biggest lever for managing it is when the two teams first talk, not how many review rounds they go through afterwards.
The collateral that reaches the field is shaped less by the talent of either team and more by the process that connects them. When that process forces them into sequential opposition, the output suffers. When it gives them a shared starting point, the output improves.
The question worth asking is not whether your marketing team is creative enough or your medical team is thorough enough. It is whether the two teams first interact over a nearly finished collateral or over a blank page.